ESC Premium Access

A closer look at glucose lowering agents cardiovascular safety results and current heart failure guidelines

Event: ESC CONGRESS 2017
Topic: Diabetes, dysglycaemia and metabolic syndrome
Session type: Satellite Symposium
Sponsored by MSD
Date: 28 August 2017
Time: 18:30 - 19:15

Congress Session

4 presentations in this session

Opening remarks - A closer look at glucose lowering agents CV safety results and current heart failure guidelines.

Speaker: Doctor A. Gitt (Ludwigshafen, DE)
Thumbnail

Latest insights from the TECOS Trial: clarifying the role for dipeptidyl peptidase-4 (DPP-4) inhibitors in the treatment of cardiovascular patients with type 2 diabetes and heart failure.

Speaker: Doctor E. Peterson (Dallas, US)
Thumbnail

Roundtable discussion: what can we learn from current guidelines – Do they accurately reflect current knowledge and what can we expect over time?

Speaker: Doctor E. Peterson (Dallas, US)
Speaker: Professor L. Ryden (Stockholm, SE)
Thumbnail

Closing remarks - A closer look at glucose lowering agents cardiovascular safety results and current heart failure guidelines.

Speaker: Doctor A. Gitt (Ludwigshafen, DE)
Thumbnail

5 speakers from this session

Doctor Anselm Kai Gitt

Klinikum Ludwigshafen, Ludwigshafen (Germany)
12 presentations
0 follower

Doctor Eric Peterson

UT Southwestern Medical Center, Dallas (United States of America)
13 presentations
0 follower

Doctor Eric Peterson

UT Southwestern Medical Center, Dallas (United States of America)
13 presentations
0 follower

Professor Lars Ryden

Karolinska Institute, Stockholm (Sweden)
32 presentations
0 follower

Doctor Anselm Kai Gitt

Klinikum Ludwigshafen, Ludwigshafen (Germany)
12 presentations
0 follower

This platform is supported by

logo Novo Nordisk